108 related articles for article (PubMed ID: 31402147)
21. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
22. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
23. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
[TBL] [Abstract][Full Text] [Related]
24. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
25. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
27. Excellent local tumor control regardless of extent of surgical resection after treatment on the Chicago Pilot II protocol for neuroblastoma.
Browne M; Kletzel M; Cohn SL; Seshadri R; Reynolds M
J Pediatr Surg; 2006 Jan; 41(1):271-6. PubMed ID: 16410146
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
29. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
30. Identification of
Shao F; Wang Z; Wang S
DNA Cell Biol; 2021 Feb; 40(2):332-347. PubMed ID: 33393844
[TBL] [Abstract][Full Text] [Related]
31. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
32. ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression.
Watanabe Y; Ishizuka Y; Hirano T; Nagasaki-Maeoka E; Hoshi R; Yoshizawa S; Uekusa S; Kawashima H; Sugito K; Shinohara K; Fukuda N; Nagase H; Soma M; Koshinaga T; Fujiwara K
Med Oncol; 2017 Aug; 34(9):158. PubMed ID: 28791558
[TBL] [Abstract][Full Text] [Related]
33. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
34. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
[TBL] [Abstract][Full Text] [Related]
35. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
[TBL] [Abstract][Full Text] [Related]
36. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
[TBL] [Abstract][Full Text] [Related]
37. Significance of survivin mRNA expression in prognosis of neuroblastoma.
Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787
[TBL] [Abstract][Full Text] [Related]
38. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
Tumer S; Altungoz O; Bagci O; Olgun HN
Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
[TBL] [Abstract][Full Text] [Related]
39. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
40. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
